设为首页 加入收藏 |
![]() |
![]() |
当前位置: |
TOP | |||||||||||||||||||||||||||||||||||||||
Herceptin150 mg powder for concentrate for solution for infu(十六)
TTP = time to progression; "ne" indicates that it could not be estimated or it was not yet reached. 1. Study H0649g: IHC3+ patient subset 2. Study H0648g: IHC3+ patient subset 3. Study M77001: Full analysis set (intent-to-treat), 24 months results Combination treatment with Herceptin and anastrozole Herceptin has been studied in combination with anastrozole for first line treatment of metastatic breast cancer in HER2 overexpressing, hormone-receptor (i.e. estrogen-receptor (ER) and/or progesterone-receptor (PR)) positive postmenopausal patients. Progression free survival was doubled in the Herceptin plus anastrozole arm compared to anastrozole (4.8 months versus 2.4 months). For the other parameters the improvements seen for the combination were for overall response (16.5 % versus 6.7 %); clinical benefit rate (42.7 % versus 27.9 %); time to progression (4.8 months versus 2.4 months). For time to response and duration of response no difference could be recorded between the arms. The median overall survival was extended by 4.6 months for patients in the combination arm. The difference was not statistically significant, however more than half of the patients in the anastrozole alo
|
|
|||
首页 上一页 13 14 15 16 17 18 19 下一页 尾页 16/25/25 | |||
【大 中 小】【打印】 【繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部】 | |||
上一篇:Inlyta 1 mg 3mg, 5 mg & 7mg fil.. | 下一篇:Gliadel 7.7mg Implant |
相关栏目 | |||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||
最新文章 |
图片主题 |
热门文章 |
推荐文章 |
相关文章 |
广告位 |